• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

May 2019 Update on Clinical Trials in PAH

May 30, 2019 By Dr. Jeremy Feldman

update

Sustained Release Beraprost

This study looked at the addition of sustained release beraprost or placebo added to inhaled Tyvaso. United Therapeutics, the study sponsor, announced that there was no benefit found.  This will probably be the end of the road for the molecule beraprost. Many years ago the non-sustained release formulation was studied in PAH but it was shelved after a major study showed no improvement in walk distance.  The second major negative study now likely means that no further studies will be pursued. 

Oral Treprostinil

The FREEDOM-EV study reported positive results after several years.  This long-term study looked at the addition of oral treprostinil (Orenitram) or placebo to background single agent therapy (patients who were on either sildenafil, tadalafil, ambrisentan, bosentan).  There was a reduction in the rate of clinical worsening with oral treprostinil.  Unfortunately, this study was 5 years late.  The standard of care has moved forward since the trial began.  Most patients now are on an ERA and a PDE5 inhibitor.  Although positive, the study does not provide much information about how oral treprostinil would benefit patients on two background therapies.  

Inhaled Treprostinil

Liquidia Technologies recently announced that their phase 3 study of inhaled treprostinil using a novel dry powder inhaler met its primary endpoint.  The novel delivery system was safe and easy to use.  In contrast to the available complicated delivery system—Tyvaso, the new device takes about 20 seconds to do a treatment.  We expect this medication/delivery system to gain FDA approval and be available in the not too distant future.  

Inhaled Nitric Oxide in PAH

Bellerophon Therapeutics recently stopped their clinical trial involving portable inhaled nitric oxide in patients with PAH.  After looking at mid-study results, the data safety monitoring committee recommended stopping the study for futility—no way for the study to be positive.  This is not very surprising as the design of the study excluded the small portion of patients who were brisk responders.  

In contrast to the negative results in PAH, preliminary positive results were found in patients with pulmonary fibrosis and that study continues.  

Ralinapag

Arena Pharmaceutical’s study of the second-generation oral prostaglandin agonist (cousin to Selexipag) moves forward with two new phase 3 studies.  

Akros

Just prior to starting their study in PAH, Akros announced that they were cancelling the study. Little information has been shared with the PAH community.  

Stay tuned for more updates. 

Filed Under: Pulmonary Hypertension Treatments

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

PAH patient with cold or flu virus

Flu Vaccine for PAH Patients

By Dr. Jeremy Feldman

It is hard to believe that summer is almost over and fall is about to begin.  As kids get ready to go back to school we

allergies with pulmonary hypertension

3 Tips to Help PAH Patients Cope with Allergies

By Dr. Jeremy Feldman

You know what they say: April showers bring May flowers…..and allergies. The nasal congestion, running nose, itchy

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives